Table 4.
Treatment and outcomes for 21 individuals with MIS-C who had received a COVID-19 vaccine
| Total (n=21) | Laboratory evidence of SARS-CoV-2 infection (n=15) | No laboratory evidence of SARS-CoV-2 infection (n=6) | ||
|---|---|---|---|---|
| Inpatient MIS-C treatment | ||||
| Intravenous immunoglobulin | 17 (81%) | 13 (87%) | 4 (67%) | |
| Systemic steroids | 16 (76%) | 12 (80%) | 4 (67%) | |
| Immune modulators | 5 (23%) | 5 (33%)* | 0 (0%) | |
| Remdesivir | 1 (5%) | 1 (7%)† | 0 (0%) | |
| None | 3 (14%) | 1 (7%) | 2 (33%) | |
| Admitted to intensive care unit | 12 (57%) | 8 (53%) | 4 (67%) | |
| Vasopressors | 8 (38%) | 6 (40%) | 2 (33%) | |
| Invasive mechanical ventilation | 3 (14%) | 2 (13%) | 1 (17%) | |
| Length of hospitalisation, days | 6 (4–9, 2–21) | 7 (4–9, 2–20) | 6 (5–7, 3–7) | |
| Discharged home | 21 (100%) | 15 (100%) | 6 (100%) | |
| Discharge MIS-C medications | ||||
| Systemic steroids | 15 (71%) | 11 (73%) | 4 (67%) | |
| Aspirin | 14 (67%) | 10 (67%) | 4 (67%) | |
| Enoxaparin | 2 (10%) | 2 (13%) | 0 (0%) | |
| Angiotensin-converting enzyme inhibitors | 2 (10%) | 2 (13%) | 0 (0%) | |
| Other‡ | 2 (10%) | 2 (13%) | 0 (0%) | |
| None | 4 (19%) | 2 (13%) | 2 (33%) | |
Data are n (%) or median (IQR, range). MIS-C=multisystem inflammatory syndrome in children. NAAT=nucleic acid amplification test.
*
Three individuals treated with anakinra, and two individuals treated with infliximab.
†
In addition, one individual (not counted here) with a positive SARS-CoV-2 NAAT during MIS-C illness received an unspecified antiviral medication.
‡
Anakinra, furosemide, and metoprolol.